Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Nucleome Therapeutics has raised $42.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Nucleome Therapeutics's investors include Oxford Science Enterprises, Creative Destruction Lab, Pfizer Venture Investments, M Ventures, British Patient Capital.
Nucleome Therapeutics is headquartered in Oxford, United Kingdom.
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Nucleome Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nucleome Therapeutics — Funding & Investors." VCBacked, October 19, 2022, https://www.vcbacked.co/company/nucleome-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Nucleome Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nucleome-therapeutics
{{cite web |title=Nucleome Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nucleome-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated